Alpha Tau Medical Ltd. (DRTS) Key Metrics
DRTS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.14B
- Enterprise value
- $1.31B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 31.8 10-yr median 3.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.22
DRTS key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDRTS valuation Price multiples at each fiscal year-end price.
DRTS returns How much profit the business earns on the capital it uses.
DRTS per-share figures Results divided by the shares outstanding at year-end.
DRTS financial health Debt, liquidity and how easily interest is covered.
DRTS efficiency & capital use Working capital cycle and where the cash goes.
DRTS valuation history
DRTS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DRTS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DRTS price vs earnings per share
DRTS key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $398.9M | $216.8M | $208.8M | $202.0M | $664.0M | — | — |
| Enterprise value | $335.7M | $169.7M | $140.3M | $102.7M | $686.7M | — | — |
| Price / book | 5.2 | 3.5 | 2.5 | 1.9 | — | — | — |
| Earnings yield | −10.7% | −14.6% | −14.0% | −16.7% | −4.1% | — | — |
| Free cash flow yield | −8.2% | −10.2% | −11.7% | −12.3% | −2.2% | — | — |
| Share price at fiscal year-end | $4.95 | $3.10 | $3.01 | $3.18 | $9.82 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.53 | −$0.45 | −$0.42 | −$0.53 | −$0.40 | −$0.13 | −$0.13 |
| Operating cash flow per share | −$0.33 | −$0.28 | −$0.26 | −$0.38 | −$0.17 | −$0.11 | −$0.10 |
| Free cash flow per share | −$0.41 | −$0.31 | −$0.35 | −$0.39 | −$0.22 | −$0.16 | −$0.12 |
| Cash per share | $0.95 | $0.85 | $1.18 | $1.65 | $0.46 | $0.68 | $0.42 |
| Book value per share | $0.96 | $0.90 | $1.22 | $1.66 | −$0.51 | −$0.12 | −$0.00 |
| Tangible book value per share | $0.96 | $0.90 | $1.22 | $1.66 | −$0.51 | −$0.12 | −$0.00 |
| Capex per share | $0.08 | $0.03 | $0.09 | $0.01 | $0.04 | $0.06 | $0.02 |
| Debt per share | $0.17 | $0.18 | $0.19 | $0.08 | $0.80 | $0.80 | — |
| Shares outstanding | 80.6M | 69.9M | 69.4M | 63.5M | 67.6M | 67.6M | 67.6M |
| Change in shares outstanding | +15.2% | +0.8% | +9.2% | −6.0% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −61.0% | −43.2% | −30.7% | −95.3% | — | — | — |
| Return on invested capital (ROIC) | −226.3% | −180.4% | −253.0% | — | — | — | — |
| Return on assets (ROA) | −44.2% | −32.8% | −25.6% | −41.6% | −57.3% | −21.0% | −26.8% |
| Return on tangible assets | −40.0% | −36.8% | −27.2% | −28.1% | −64.6% | −16.8% | −26.8% |
| Financial health | |||||||
| Total debt | $13.7M | $12.5M | $13.3M | $5.2M | $54.0M | $54.0M | — |
| Cash & short-term investments | $76.9M | $59.6M | $81.8M | $104.5M | $31.3M | $46.0M | $28.1M |
| Net debt | −$63.2M | −$47.1M | −$68.5M | −$99.3M | $22.6M | $7.9M | −$28.1M |
| Debt / equity | 0.18 | 0.20 | 0.16 | 0.05 | — | — | — |
| Debt / assets | 0.13 | 0.15 | 0.12 | 0.04 | 1.28 | 1.02 | — |
| Current ratio | 7.45 | 7.40 | 12.07 | 24.55 | 7.41 | 22.73 | 22.11 |
| Quick ratio | 7.45 | 7.40 | 12.08 | 24.79 | 9.26 | 37.02 | 21.27 |
| Interest coverage | -100.9 | -119.0 | -475.7 | -18.2 | -1.1 | -42.6 | -6.2 |
| Working capital | $67.8M | $55.6M | $78.7M | $102.1M | $28.2M | $45.4M | $28.5M |
| Invested capital | $13.9M | $15.6M | $16.0M | $6.3M | −$12.1M | −$480,000 | −$28.3M |
| Tangible asset value | $77.1M | $62.7M | $84.5M | $105.7M | −$34.8M | −$8.4M | −$193,000 |
| Net current asset value | $48.8M | $40.7M | $62.8M | $92.0M | −$44.4M | −$14.0M | −$1.9M |
| Graham net-net per share | $0.59 | $0.52 | $0.85 | $1.41 | −$0.73 | −$0.44 | −$0.04 |
| Capital allocation | |||||||
| Capex / depreciation | 4.93 | 2.03 | 5.96 | 0.92 | 3.77 | 43.80 | 19.59 |
| Efficiency | |||||||
| Days of inventory on hand | — | — | -184.2 | -1,721.4 | -8,940.4 | -60,933.1 | — |
| Days payables outstanding | 1,096.0 | 1,009.7 | 677.8 | 489.5 | 509.6 | 3,940.7 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.33 | 0.36 | 0.54 | 0.75 | 0.72 | 0.09 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $184,000 | $338,000 | $188,000 | $256,000 | $478,500 | $309,000 | $141,000 |
| Average payables | $3.7M | $3.0M | $2.0M | $1.3M | $1.1M | $928,500 | $893,000 |
| Average inventory | — | — | −$542,000 | −$4.6M | −$19.0M | −$14.4M | $1.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DRTS's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DRTS valuation and financial ratios
Alpha Tau Medical earned a return on equity of −61.0% and a return on invested capital of −226.3% in fiscal 2025. It ended the year with $13.7 million of debt and $76.9 million in cash and short-term investments, a net cash position of $63.2 million. The share count rose 19.2% from 67.6M to 80.6M over 6 years.
See the DRTS income statement, the DRTS chart for price history, or the DRTS stock overview for the latest quote and news.
DRTS key metrics FAQ
What is Alpha Tau Medical's return on equity?
Alpha Tau Medical's return on equity (ROE) was −61.0% in fiscal 2025: net income of -$42.6 million on average shareholders' equity of $69.9 million.
What is Alpha Tau Medical's ROIC?
Alpha Tau Medical's return on invested capital was −226.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Alpha Tau Medical have?
Alpha Tau Medical had total debt of $13.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
What is Alpha Tau Medical's free cash flow yield?
Alpha Tau Medical generated -$32.8 million of free cash flow in fiscal 2025, a free cash flow yield of −8.2% on its market value at year-end ($398.9 million).
What is Alpha Tau Medical's current ratio?
Alpha Tau Medical's current ratio was 7.45 at the end of fiscal 2025: current assets were 7.45 times current liabilities.